Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

被引:89
作者
Prado, JG
Wrin, T
Beauchaine, J
Ruiz, L
Petropoulos, CJ
Frost, SDW
Clotet, B
D'Aquila, RT
Martinez-Picado, J
机构
[1] Univ Autonoma Barcelona, Hosp Germans Trias Pujol, IrsiCaixa Fdn, Barcelona 08916, Spain
[2] Virolog Inc, San Francisco, CA USA
[3] Univ Calif San Diego, Dept Pathol, San Diego, CA USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
关键词
amprenavir; HIV-1 drug resistance; lopinavir; protease inhibitors; replication capacity; viral fitness;
D O I
10.1097/00002030-200205030-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate protease inhibitor (PI) cross-resistance and reductions in replication capacity conferred by amprenavir-selective mutations. Methods: HIV-1(IIIB) variants derived from passage in increasing concentrations of amprenavir were studied, as well as 3'Gag/protease recombinants derived from them. These strains progressively accumulated mutations at codons 10, 46, 47, 50 and 84 in the protease as well as a p1/p6 cleavage site mutation at codon 449 in Gag. Their susceptibility (IC50) to various PI and their corresponding replication capacities were evaluated by a single-cycle growth assay and compared with measures using competitive cultures and p24 antigen production. Results: Amprenavir susceptibility decreased with increasing numbers of protease mutations. Changes in lopinavir susceptibility paralleled changes in amprenavir susceptibility. Certain amprenavir-selected mutants conferred greater than 10-fold cross-resistance to lopinavir, including PrL10F/M461/150V-GagL449F (19-fold) and PrL10F/M46I/147V/150V-GagL449F (31-fold). Moreover, one isolate with only two mutations in the protease (L10F/84V) and GagL449F displayed a 7.7-fold increase in lopinavir IC50. Low-level cross-resistance to ritonavir and nelfinavir was also observed. The replication capacity of viruses containing either 184V or 150V was at least 90% lower than the reference virus in the single-cycle assay. The order of relative replication capacity was wild-type > L10F > L10F/184V > L10F/M461/150V > L10F/M461/147V/150V. Conclusion: These results indicate that until more comprehensive genotype-phenotype correlations between amprenavir and lopinavir susceptibility are established, phenotypic testing may be preferable to genotyping to detect cross-resistance, and should be considered when switching patients from a failing amprenavir-containing regimen. This study also provides data on the concordance of replication capacity measurements generated using rapid single-cycle growth and competition assays. (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:1009 / 1017
页数:9
相关论文
共 30 条
[1]  
ALFORD JL, 1999, 3 INT WORKSH HIV DRU
[2]   Resistance to human immunodeficiency virus type 1 protease inhibitors [J].
Boden, D ;
Markowitz, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2775-2783
[3]   In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor [J].
Carrillo, A ;
Stewart, KD ;
Sham, HL ;
Norbeck, DW ;
Kohlbrenner, WE ;
Leonard, JM ;
Kempf, DJ ;
Molla, A .
JOURNAL OF VIROLOGY, 1998, 72 (09) :7532-7541
[4]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480
[5]  
DEPASQUALE MP, 1998, 2 INT WORKSH HIV DRU
[6]   Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors [J].
Doyon, L ;
Croteau, G ;
Thibeault, D ;
Poulin, F ;
Pilote, L ;
Lamarre, D .
JOURNAL OF VIROLOGY, 1996, 70 (06) :3763-3769
[7]  
Erickson JW, 1999, AIDS, V13, pS189
[8]  
GAMARNIK A, 2000, 4 INT WORKSH HIV DRU
[9]   Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir- experienced subjects: AIDS Clinical Trials Group protocol 373 [J].
Gulick, RM ;
Smeaton, LM ;
D'Aquila, RT ;
Eron, JJ ;
Currier, JS ;
Gerber, JG ;
Acosta, E ;
Sommadossi, JP ;
Tung, R ;
Snyder, S ;
Kuritzkes, DR ;
Murphy, RL .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (05) :715-721
[10]  
HELLMANN N, 1999, 39 INT C ANT AG CHEM